Sarepta Therapeutics Inc (NASDAQ:SRPT) — Market Cap & Net Worth
Market Cap & Net Worth: Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics Inc (NASDAQ:SRPT) has a market capitalization of $1.76 Billion ($1.76 Billion) as of June 26, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6701 globally and #2027 in its home market, demonstrating a 5.87% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sarepta Therapeutics Inc's stock price $16.70 by its total outstanding shares 105576222 (105.58 Million). Review Sarepta Therapeutics Inc (SRPT) total liabilities to assess the company's total debt and financial obligations.
Sarepta Therapeutics Inc Market Cap History: 2015 to 2026
Sarepta Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $4.07 Billion to $1.76 Billion (-4.54% CAGR).
Index Memberships
Sarepta Therapeutics Inc is a constituent of 5 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$922.91 Billion | 0.19% | #28 of 30 |
|
NASDAQ Health Care
IXHC
|
$2.44 Trillion | 0.07% | #176 of 976 |
|
NASDAQ Composite
IXIC
|
$40.11 Trillion | 0.00% | #728 of 3165 |
|
S&P Midcap 400
MID
|
$3.54 Trillion | 0.19% | #379 of 401 |
|
NASDAQ Biotechnology
NBI
|
$1.71 Trillion | 0.10% | #112 of 263 |
Weight: Sarepta Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Sarepta Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sarepta Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.03x
Sarepta Therapeutics Inc's market cap is 1.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.90 Billion | $5.42 Million | -$267.26 Million | 534.21x | N/A |
| 2017 | $5.87 Billion | $154.58 Million | -$50.69 Million | 38.00x | N/A |
| 2018 | $11.52 Billion | $301.03 Million | -$361.92 Million | 38.27x | N/A |
| 2019 | $13.62 Billion | $380.83 Million | -$715.08 Million | 35.77x | N/A |
| 2020 | $18.00 Billion | $540.10 Million | -$554.13 Million | 33.33x | N/A |
| 2021 | $9.51 Billion | $701.89 Million | -$418.78 Million | 13.55x | N/A |
| 2022 | $13.68 Billion | $933.01 Million | -$703.49 Million | 14.66x | N/A |
| 2023 | $10.18 Billion | $1.24 Billion | -$535.98 Million | 8.19x | N/A |
| 2024 | $12.84 Billion | $1.90 Billion | $235.24 Million | 6.75x | 54.57x |
| 2025 | $2.27 Billion | $2.20 Billion | -$713.41 Million | 1.03x | N/A |
Competitor Companies of SRPT by Market Capitalization
Companies near Sarepta Therapeutics Inc in the global market cap rankings as of June 26, 2026.
Key companies related to Sarepta Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #219 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #438 globally with a market cap of $64.23 Billion USD.
- UCB SA (BR:UCB): Ranked #546 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #219 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $475.20 |
| #438 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.23 Billion | $623.43 |
| #546 | UCB SA | BR:UCB | $49.68 Billion | €255.00 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €748.60 |
Sarepta Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Sarepta Therapeutics Inc's market cap moved from $4.07 Billion to $ 1.76 Billion, with a yearly change of -4.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.76 Billion | -22.42% |
| 2025 | $2.27 Billion | -82.30% |
| 2024 | $12.84 Billion | +26.09% |
| 2023 | $10.18 Billion | -25.58% |
| 2022 | $13.68 Billion | +43.90% |
| 2021 | $9.51 Billion | -47.18% |
| 2020 | $18.00 Billion | +32.12% |
| 2019 | $13.62 Billion | +18.24% |
| 2018 | $11.52 Billion | +96.14% |
| 2017 | $5.87 Billion | +102.84% |
| 2016 | $2.90 Billion | -28.90% |
| 2015 | $4.07 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 25th, 2026 the market cap of Sarepta Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.76 Billion USD |
| MoneyControl | $1.76 Billion USD |
| MarketWatch | $1.76 Billion USD |
| marketcap.company | $1.76 Billion USD |
| Reuters | $1.76 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 ski… Read more